Logan Melchione, Vice President of Patient Affordability at Paysign, has highlighted the growing impact of maximizers on patient affordability and pharmaceutical manufacturers’ copay strategies. In a recent analysis, Melchione discussed the limitations of traditional copay solutions in addressing these challenges and detailed Paysign’s data-driven approach to identifying the effects of maximizers during the first-fill process. She also shared insights into how this methodology has reportedly saved millions while improving patient access to medications.
Maximizers, which are programs designed to optimize copay assistance for patients with high-cost therapies, have significantly reshaped the landscape of patient affordability. According to Melchione, these programs often place pressure on pharmaceutical manufacturers to adapt their strategies in order to maintain accessibility for patients. Paysign’s approach involves leveraging data analytics to assess the exposure risk posed by maximizers and identify their impact early in the prescription process. The company claims that this proactive strategy not only mitigates financial strain but also enhances access for patients who rely on critical medications. For those interested in further analysis or exploring Paysign’s solutions, inquiries can be directed via email or through their website.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
Date: June 6, 2025
發佈留言